Yükleniyor... / Loading...
Apheresis of Patients With Immunodeficiency
Bu çalışma, DOCK8 eksikliği, LAD-1 veya GATA2 eksikliği gibi genetik immün yetmezlikleri olan hastalardan araştırma amaçlı kan hücresi toplama (aferez) işlemini kapsıyor. Bu tanılardan biri doğrulanmış 18-40 yaş arası hastalar dahil edilir. Faz uygulanmayan gözlemsel bir çalışmadır; şu anda katılımcı almaktadır (recruiting).
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
-INCLUSION CRITERIA - PATIENT:
1. Individuals age 18-40 years.
2. Diagnosis of DOCK8 deficiency, LAD-1, or GATA2 Deficiency:
-DOCK8 deficiency
* Homozygous or compound heterozygous mutations in the DOCK8 gene.
-LAD-1
* Less than 10% CD18 expression on the neutrophil surface.
-GATA2 Deficiency
* Deleterious mutation of GATA2 Gene
3. Serum creatinine \<1.5 mg/dL.
4. Total Bilirubin \< 3mg/dl, ALT and AST \< 5X upper limit of normal.
5. Ability to give informed consent.
6. Adequate venous access for peripheral apheresis, or consent to use a temporary central venous catheter for apheresis.
7. Individuals of childbearing age must have a negative urine pregnancy test within one week prior to beginning filgrastim or filgrastim biosimilar administration.
EXCLUSION CRITERIA- PATIENT:
1. HIV infection.
2. Chronic hepatitis B or hepatitis C virus infection.
3. History of psychiatric disorder which may compromise compliance with protocol, or which does not allow for appropriate informed consent.
4. Active infection that is not responding to antimicrobial therapy.
5. Pregnant Individuals may not participate per OHSRP SOP.
6. Any Individual who is breastfeeding as the effects of filgrastim or filgrastim biosimilar product on infants is not known.
7. Sexually active individuals capable of becoming pregnant who are unable or unwilling to use effective form(s) of contraception during the 10 days surrounding filgrastim or filgrastim biosimilar product administration and apheresis procedure(s). Effective forms of contraception include one or more of the following: intrauterine device (IUD), hormonal (birth control pills, injections, or implants), tubal ligation/hysterectomy, partner s vasectomy, barrier methods, (condom, diaphragm, or cervical cap), or abstinence. Males on the protocol must use an effective form of contraception at study entry.
8. Presence of active malignancy in another organ system other than the hematopoietic system.
9. Individuals with active pulmonary disease.
10. History of hypertension that is not controlled by medication, stroke, or severe heart disease. Individuals with symptomatic angina will be considered to have severe heart disease and will not be eligible.
11. Other medical contraindications to stem cell donation (i.e., severe atherosclerosis, autoimmune disease, iritis or episcleritis, deep venous thrombosis, cerebrovascular accident).
12. Thrombocytopenia (platelets less than 50,000 per microliter) at baseline evaluation.
13. Individuals receiving experimental therapy or investigational agents.
14. Sensitivity to filgrastim, to E. Coli derived products, or to a biosimilar recombinant protein to filgrastim.
15. Individuals must test negative for transfusion-transmissible infectious agents, including hepatitis B (HBsAg), hepatitis C (anti-HCV), HIV (anti-HIV-1/2).